How are energy investors positioned?
ASILOMAR, Calif. - Bruker Corporation (BRKR), a $5.5 billion scientific instruments manufacturer with a robust 50% gross profit margin, has announced the launch of the world’s first 1.3 GHz high-resolution Nuclear Magnetic Resonance (NMR) spectrometer. The unveiling took place at the Joint ENC-ISMAR Conference 2025, marking a significant advancement in NMR research capabilities for biomolecular and materials science.
The new spectrometer is equipped with a standard-bore 54 mm superconducting magnet that achieves a field strength of 30.5 Tesla, made possible by incorporating a novel high-temperature superconductor insert. This technology maintains the same physical dimensions and cryogen consumption as previous models, while slightly increasing the stray field radius.
Bruker’s 1.3 GHz NMR spectrometer provides enhanced resolution and sensitivity, allowing scientists to study complex biomolecular systems and advanced materials with greater detail. Testing of the spectrometer involved five different NMR probe configurations, producing high-resolution liquids and solids NMR spectra at the 1.3 GHz proton frequency. These tests demonstrated the spectrometer’s potential for groundbreaking research in biomolecular and materials science.
The increased magnetic field strength is particularly advantageous for the spectroscopy of bio-macromolecules that lack dispersion, such as carbohydrates and intrinsically disordered proteins. The spectrometer offers new strategies for obtaining atomic resolution in the study of these molecules’ dynamics and function. In the realm of materials science, the technology is crucial for studying quadrupolar nuclei, where the increased field leads to narrower spectral lines and enhanced chemical shift tensor measurement capabilities.
Dr. Falko Busse, President of the Bruker BioSpin Group, expressed confidence that the high-resolution GHz-class NMR spectrometers will allow researchers to advance scientific understanding in both biomolecular systems and materials science.
Feedback from the scientific community has been positive. Dr. Takanori Kigawa from the RIKEN Yokohama Institute in Japan praised the spectrometer’s gain in resolution and sensitivity, while Dr. Pierre Florian from CEMHTI-CNRS Orléans, France, noted the improved ability to resolve different atomic environments in complex materials.
Bruker, a leader in the development of scientific instruments for molecular and materials research, continues to support advancements in life science and diagnostics with its innovative solutions. The company’s contributions are aimed at enhancing productivity and customer success across various scientific domains. According to InvestingPro data, Bruker has demonstrated strong business fundamentals with 13.5% revenue growth in the last twelve months, though its stock currently trades near its 52-week low, potentially presenting an opportunity for investors. For detailed analysis and 10+ additional ProTips about Bruker’s financial health and market position, explore the comprehensive Pro Research Report available on InvestingPro.
This development is expected to open new avenues for research and discovery, as stated in a press release by Bruker Corporation. With positive net income expectations for the coming year and strong cash flows to cover interest payments, the company appears well-positioned to continue its innovation trajectory. Discover more insights about Bruker and similar investment opportunities through InvestingPro’s extensive financial analysis tools and expert research reports.
In other recent news, Bruker Corporation reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.76, compared to the forecast of $0.74. The company’s revenue also exceeded projections, reaching $979.6 million against the expected $962.38 million, marking a 14.6% year-over-year increase. In addition to its financial performance, Bruker has made significant strides in technological advancements, including the installation of a novel MRI polarizer at UCSF for cancer research and the launch of the X4 POSEIDON, a new benchtop 3D X-ray microscope system. Furthermore, Bruker announced advancements in proteomics technology at the US HUPO Conference, enhancing capabilities in single-cell proteomics and glycoproteomics analysis. The company also appointed Laura Francis as an independent director to its board, with her joining the Audit Committee as a financial expert. Despite these positive developments, the company’s stock experienced a slight decline, which may reflect broader market trends or investor caution regarding future guidance. Analyst firms have not issued any recent upgrades or downgrades for Bruker, but the company continues to focus on strategic acquisitions and innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.